Pharmacyte Biotech, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pharmacyte Biotech, Inc. on September 28, 2015. The report addresses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate event and does not contain financial statements.
Material Changes
The material change reported is the effective resignation of Richard M. Goldfarb, MD, from his position as a member of the Board of Directors. While Dr. Goldfarb's intent to resign was previously disclosed in a September 29, 2014 filing, the Chief Executive Officer determined the effective date of the resignation to be September 28, 2015.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the departure of the director.
Key Facts for Investors to Verify
- Richard M. Goldfarb, MD, is no longer a member of the Board of Directors as of September 28, 2015.
- The resignation was finalized by the Chief Executive Officer, Kenneth L. Waggoner, approximately one year after the initial notice was received.
- Investors should review the company's most recent 10-K or 10-Q filings for current financial performance, as this 8-K contains no financial data.